Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Athenex Inc (NQ: ATNX )

12.10 USD +0.23 (+1.94%)
Official Closing Price Updated: 7:59 PM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,873,000
Open 12.00
Bid (Size) 12.25 (5)
Ask (Size) 12.83 (1)
Prev. Close 11.87
Today's Range 11.69 - 12.37
52wk Range 5.630 - 15.24
Shares Outstanding 63,543,559
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Athenex to Provide a Corporate and Financial Update for the Fourth Quarter and Full Year 2020 on March 1, 2021
From GlobeNewswire News Releases
Almirall U.S. Launches Klisyri® (tirbanibulin), a New, Innovative Topical Treatment for Actinic Keratosis
- Actinic keratosis (AK), the second most common diagnosis made by dermatologists in the United States(1), affects more than 40 million Americans each year(2) 
From PR Newswire

Performance

YTD
+6.89%
+6.89%
1 Month
-6.56%
-6.56%
3 Month
-11.23%
-11.23%
6 Month
+5.31%
+5.31%
1 Year
-0.98%
-0.98%

More News

Read More
Athenex Announces U.S. Launch of Klisyri® and Licensing of Additional Territories for Tirbanibulin
From GlobeNewswire News Releases
Athenex Announces New England Journal of Medicine Publication of Phase III Data on the Efficacy and Safety of Klisyri® (tirbanibulin)
From GlobeNewswire News Releases
Almirall announces New England Journal of Medicine publication of Phase III data demonstrating efficacy and safety of Klisyri® (tirbanibulin)
From PR Newswire
CEO Dr. Johnson Lau Recuperating from COVID at Home
From GlobeNewswire News Releases
CEO Dr. Johnson Lau Contracts COVID-19
From GlobeNewswire News Releases
Athenex to Present at the 39th Annual J.P. Morgan Healthcare Conference
From GlobeNewswire News Releases
Athenex's Earnings Outlook
Tags Market News ATNX BZI/EP
From Benzinga
Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp
From GlobeNewswire News Releases
Look Under The Hood: LABU Has 38% Upside
Tags ETFs
From ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.